About Supernus Pharmaceuticals (NASDAQ:SUPN)
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.
Industry, Sector and Symbol
Trailing P/E Ratio34.82
Forward P/E Ratio23.90
Sales & Book Value
Annual Sales$302.24 million
Price / Sales7.62
Cash Flow$1.51 per share
Price / Cash29.67
Book Value$5.22 per share
Price / Book8.56
Net Income$57.28 million
Return on Equity28.07%
Return on Assets18.12%
Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions
What is Supernus Pharmaceuticals' stock symbol?
Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
How were Supernus Pharmaceuticals' earnings last quarter?
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) announced its quarterly earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.18. The specialty pharmaceutical company earned $88.44 million during the quarter, compared to the consensus estimate of $87.84 million. Supernus Pharmaceuticals had a net margin of 18.95% and a return on equity of 28.07%. View Supernus Pharmaceuticals' Earnings History.
When will Supernus Pharmaceuticals make its next earnings announcement?
Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2018?
10 analysts have issued 1 year target prices for Supernus Pharmaceuticals' stock. Their predictions range from $41.00 to $66.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $51.90 in the next year. View Analyst Ratings for Supernus Pharmaceuticals.
What are Wall Street analysts saying about Supernus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (1/12/2018)
- 2. FBR & Co analysts commented, "We are initiating coverage of Supernus Pharmaceuticals (SUPN) with a Buy rating and a 12-month price target of $53 per share. We see strong revenue growth exceeding 25% per year for 2017–2019 with in-line drugs Trokendi XR (epilepsy/ migraine) and Oxtellar XR (epilepsy) driving growth. Starting in 2020, we expect contribution from late-stage pipeline drugs SPN-812, which is a non-stimulant ADHD drug, and SPN-810 for impulsive aggression. We model EPS at $1.05 in 2017, $1.70 in 2018, and $2.35 in 2019 including a full tax rate. Our 2017 EPS estimate compares unfavorably to 2016, which included a tax benefit of $40.8 million or ~$0.80 per share. Our price target averages our DCF valuation and a P/E-derived target, which is 35x 2018E EPS of $1.70 discounted to present at 10%. At current prices, the shares have corrected by ~18% from all-time highs after an update on pipeline drug SPN-810 raised risks on timing/approvability. We see this drop as an opportunity to establish positions." (10/19/2017)
- 3. Cantor Fitzgerald analysts commented, "Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day." (9/19/2017)
Who are some of Supernus Pharmaceuticals' key competitors?
Some companies that are related to Supernus Pharmaceuticals include Integra Lifesciences (IART), FibroGen (FGEN), Indivior (INVVY), Taro Pharmaceutical Industries (TARO), ABLYNX (ABLYF), Hikma Pharmaceutic (HKMPF), Ligand Pharmaceuticals (LGND), Loxo Oncology (LOXO), Array Biopharma (ARRY), Advanced Accelerator Application (AAAP), ACADIA Pharmaceuticals (ACAD), Halozyme Therapeutics (HALO), Clovis Oncology (CLVS), Evotec (EVTCY), Puma Biotechnology (PBYI), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT) and Amicus Therapeutics (FOLD).
Who are Supernus Pharmaceuticals' key executives?
Supernus Pharmaceuticals' management team includes the folowing people:
- Charles W. Newhall III, Independent Chairman of the Board (Age 72)
- Jack A. Khattar, President, Chief Executive Officer, Secretary, Director (Age 55)
- Gregory S. Patrick Ph.D., Chief Financial Officer, Vice President (Age 65)
- Stefan K. F. Schwabe M.D. Ph.D., Executive Vice-President - Research and Development, Chief Medical Officer (Age 65)
- Padmanabh P. Bhatt Ph.D., Senior Vice President - Intellectual Property, Chief Scientific Officer (Age 59)
- Victor Vaughn, Senior Vice President - Sales and Marketing (Age 59)
- Georges Gemayel Ph.D., Independent Director (Age 56)
- Frederick M. Hudson CPA, Independent Director (Age 71)
- John M. Siebert Ph.D., Independent Director (Age 77)
Who owns Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.47%), Bank of New York Mellon Corp (2.79%), Rice Hall James & Associates LLC (2.58%), Acadian Asset Management LLC (2.50%), Champlain Investment Partners LLC (2.37%) and Ashford Capital Management Inc. (1.47%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.
Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Ranger Investment Management L.P., Deutsche Bank AG, Glenmede Trust Co. NA, Royce & Associates LP, Bank of New York Mellon Corp, TIAA CREF Investment Management LLC, Emerald Advisers Inc. PA and Goldman Sachs Group Inc.. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Insider Buying and Selling for Supernus Pharmaceuticals.
Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Stephens Investment Management Group LLC, Wells Fargo & Company MN, BlackRock Inc., Rice Hall James & Associates LLC, Capital Fund Management S.A., Cortina Asset Management LLC, Two Sigma Investments LP and William Blair Investment Management LLC. View Insider Buying and Selling for Supernus Pharmaceuticals.
How do I buy Supernus Pharmaceuticals stock?
Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Supernus Pharmaceuticals' stock price today?
One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $44.70.
How big of a company is Supernus Pharmaceuticals?
Supernus Pharmaceuticals has a market capitalization of $2.23 billion and generates $302.24 million in revenue each year. The specialty pharmaceutical company earns $57.28 million in net income (profit) each year or $1.06 on an earnings per share basis. Supernus Pharmaceuticals employs 422 workers across the globe.
How can I contact Supernus Pharmaceuticals?
Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]
MarketBeat Community Rating for Supernus Pharmaceuticals (SUPN)MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Supernus Pharmaceuticals (NASDAQ:SUPN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.90||2.90||2.89||2.67|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$51.90||$51.90||$49.89||$48.17|
|Price Target Upside: ||16.11% upside||32.91% upside||34.11% upside||0.77% upside|
Supernus Pharmaceuticals (NASDAQ:SUPN) Consensus Price Target History
Supernus Pharmaceuticals (NASDAQ:SUPN) Analyst Ratings History
(Data available from 3/17/2016 forward)
Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings History and Estimates Chart
Supernus Pharmaceuticals (NASDAQ SUPN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/27/2018||Q4 2017||$0.26||$0.44||$87.84 million||$88.44 million||View||N/A|
|11/6/2017||Q3 2017||$0.27||$0.29||$78.74 million||$80.40 million||View||N/A|
|8/2/2017||Q2 2017||$0.24||$0.32||$68.54 million||$75.83 million||View||Listen|
|5/9/2017||Q1 2017||$0.22||$0.19||$57.91 million||$57.58 million||View||Listen|
|2/28/2017||Q4 2016||$0.24||$0.26||$58.87 million||$62.37 million||View||N/A|
|1/20/2017||Q3 2016||$0.37||$56.23 million||$56.81 million||View||N/A|
|8/2/2016||Q2||$0.13||$0.18||$49.67 million||$50.40 million||View||Listen|
|5/3/2016||Q1||$0.09||$0.08||$45.33 million||$43.00 million||View||Listen|
|3/2/2016||Q4||$0.06||$0.14||$42.93 million||$42.70 million||View||Listen|
|11/3/2015||Q315||$0.02||$0.08||$37.93 million||$38.60 million||View||Listen|
|8/5/2015||Q215||$0.02||$0.03||$34.07 million||$35.10 million||View||Listen|
|5/5/2015||$0.02||$0.02||$29.16 million||$28.13 million||View||Listen|
|3/10/2015||Q4 2014||($0.05)||$0.08||$26.37 million||$30.80 million||View||N/A|
|11/11/2014||Q314||$0.36||$0.39||$43.10 million||$52.50 million||View||N/A|
|8/11/2014||Q214||($0.16)||$0.08||$19.85 million||$29.67 million||View||N/A|
|5/12/2014||Q114||($0.41)||($0.38)||$9.94 million||$9.00 million||View||N/A|
|3/12/2014||Q413||($0.55)||($0.65)||$7.78 million||$10.30 million||View||N/A|
|11/12/2013||Q313||($0.67)||($0.78)||$2.54 million||$1.26 million||View||Listen|
|8/13/2013||Q2 2013||($0.65)||($0.89)||$0.91 million||$0.28 million||View||N/A|
|5/13/2013||Q1 2013||($0.63)||($0.60)||$0.57 million||$0.15 million||View||N/A|
Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings Estimates
2018 EPS Consensus Estimate: $1.86
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by MarketBeat.com
Supernus Pharmaceuticals (NASDAQ SUPN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 96.31%
Supernus Pharmaceuticals (NASDAQ SUPN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/22/2018||Padmanabh P Bhatt||VP||Sell||20,000||$48.04||$960,800.00||32,500|| |
|1/17/2018||Padmanabh P Bhatt||VP||Sell||20,000||$44.98||$899,600.00||32,500|| |
|1/12/2018||Victor Vaughn||VP||Sell||5,750||$45.03||$258,922.50||15,094|| |
|1/11/2018||Gregory S. Patrick||CFO||Sell||50,000||$43.56||$2,178,000.00|| |
|1/9/2018||Victor Vaughn||VP||Sell||15,000||$42.04||$630,600.00||24,344|| |
|1/2/2018||Victor Vaughn||VP||Sell||55,000||$40.11||$2,206,050.00|| |
|9/8/2017||Gregory S. Patrick||CFO||Sell||50,000||$47.60||$2,380,000.00|| |
|9/8/2017||Padmanabh P Bhatt||SVP||Sell||5,000||$49.86||$249,300.00||12,500|| |
|9/7/2017||Stefan K.F. Schwabe||Insider||Sell||95,000||$46.59||$4,426,050.00|| |
|8/16/2017||Padmanabh P Bhatt||VP||Sell||3,709||$45.23||$167,758.07||17,500|| |
|7/12/2017||Padmanabh P Bhatt||VP||Sell||3,735||$44.90||$167,701.50||21,209|| |
|6/23/2017||Padmanabh P Bhatt||VP||Sell||2,556||$44.90||$114,764.40||24,944|| |
|6/2/2017||Padmanabh P Bhatt||VP||Sell||10,000||$39.86||$398,600.00||27,500|| |
|5/26/2017||Padmanabh P Bhatt||VP||Sell||2,500||$35.90||$89,750.00||37,500|| |
|5/25/2017||Padmanabh P Bhatt||VP||Sell||5,500||$34.90||$191,950.00||43,887|| |
|4/24/2017||Gregory S Patrick||CFO||Sell||54,000||$32.37||$1,747,980.00||54,221|| |
|4/24/2017||Padmanabh P Bhatt||VP||Sell||11,806||$32.59||$384,757.54||45,500|| |
|9/16/2016||Gregory S Patrick||CFO||Sell||2,000||$25.00||$50,000.00||3,616|| |
|7/14/2016||Gregory S. Patrick||CFO||Sell||3,395||$22.00||$74,690.00|| |
|4/11/2016||Padmanabh P Bhatt||VP||Sell||30,762||$16.49||$507,265.38||57,306|| |
|12/9/2015||Padmanabh P. Bhatt||VP||Sell||14,238||$14.90||$212,146.20||88,068|| |
|12/8/2015||M James Barrett||Director||Sell||212,970||$14.56||$3,100,843.20||115,355|| |
|11/25/2015||M James Barrett||Director||Sell||16,179||$16.35||$264,526.65||73,929|| |
|11/18/2015||M James Barrett||Director||Sell||93,000||$16.61||$1,544,730.00||73,929|| |
|11/16/2015||M James Barrett||Director||Sell||119,650||$16.24||$1,943,116.00||73,929|| |
|11/4/2015||Padmanabh P Bhatt||VP||Sell||5,000||$19.90||$99,500.00||102,306|| |
|7/16/2015||Gregory S Patrick||CFO||Sell||6,217||$20.00||$124,340.00|| |
|7/13/2015||Stefan K.F. Schwabe||EVP||Sell||1,950||$19.23||$37,498.50|| |
|6/17/2015||M James Barrett||Director||Sell||111,881||$16.39||$1,833,729.59|| |
|6/17/2015||Scott D Sandell||Major Shareholder||Sell||136,597||$16.50||$2,253,850.50|| |
|6/16/2015||M James Barrett||Director||Sell||55,105||$16.85||$928,519.25|| |
|6/16/2015||Scott D Sandell||Major Shareholder||Sell||95,437||$16.92||$1,614,794.04|| |
|6/12/2015||Stefan K.F. Schwabe||EVP||Sell||2,051||$18.27||$37,471.77|| |
|6/11/2015||Stefan K.F. Schwabe||EVP||Sell||3,631||$16.39||$59,512.09|| |
|3/24/2015||Jones W Bryan||VP||Sell||1,900||$12.00||$22,800.00|| |
|8/19/2013||Padmanabh Bhatt||VP||Sell||2,285||$8.21||$18,759.85||51,806|| |
|3/22/2013||Michael Bigham||Director||Buy||35,000||$5.41||$189,350.00|| |
|3/21/2013||John M Siebert||Director||Buy||3,000||$5.50||$16,500.00|| |
|3/15/2013||Jack A Khattar||CEO||Buy||10,000||$6.15||$61,500.00|| |
|3/14/2013||Gregory S Patrick||CFO||Buy||5,000||$6.95||$34,750.00|| |
|12/4/2012||John M Siebert||Director||Buy||7,000||$8.14||$56,980.00|| |
Supernus Pharmaceuticals (NASDAQ SUPN) News Headlines
Supernus Pharmaceuticals (NASDAQ:SUPN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Supernus Pharmaceuticals (NASDAQ:SUPN) Income Statement, Balance Sheet and Cash Flow Statement
Supernus Pharmaceuticals (NASDAQ SUPN) Stock Chart for Saturday, March, 17, 2018